PedAM
Pediatric Disease Annotations & Medicines
| Disease | lung cancer |
| Symptom | C0080032|malignant pleural effusion |
| Sentences | 27 |
| PubMedID- 20819493 | Objective: to compare the therapeutic effects of pleural perfusion of ndp and cddp in non-small cell lung cancer (nsclc) patients with malignant pleural effusion, their quality of life and toxic side effects. |
| PubMedID- 23364973 | This study aimed to evaluate the diagnostic and prognostic value of pleural crp (p-crp) in lung cancer patients with malignant pleural effusion (mpe). |
| PubMedID- 24072496 | Interleukin 17 (il-17) has been found to be increased in some human cancers; however, the possible implication of il-17 in regulating antitumor responses in lung cancer patients with malignant pleural effusions (mpe) remains to be elucidated. |
| PubMedID- 20207133 | Purpose: to investigate the feasibility, pharmacokinetics, efficacy and toxicity of intrapleural paclitaxel liposome injection in non-small cell lung cancer (nsclc) patients with malignant pleural effusions. |
| PubMedID- 20093263 | Effects of a simple intraoperative intrathoracic hyperthermotherapy for lung cancer with malignant pleural effusion or dissemination. |
| PubMedID- 23533029 | In addition, the chemokine receptor ccr6 which binds to the chemokine cc ligand 20 (ccl20) that is present in many malignant pleural effusions of lung cancer patients is highly expressed on th17 cells thus further facilitating their recruitment to sites of tumor growth and inflammation (acosta-rodriguez et al., 2007; annunziato et al., 2007, 2012). |
| PubMedID- 21224698 | A case of lung cancer with malignant pleural effusion obtained a long-time survival after intra-operative hyperthermo-chemotherapy. |
| PubMedID- 26134225 | Introduction: a subset of non-small-cell lung cancer (nsclc) patients with malignant pleural effusion and/or malignant pleural nodules is now classified as stage iv and is generally considered a contraindication to surgery. |
| PubMedID- 25207893 | Conclusion: high clinical efficacy of elemene was found in the treatment malignant pleural effusion in patients with lung cancer. |
| PubMedID- 23243596 | The first one (nct00690261; current status: recruiting) specifically aims at investigating impact of m1/m2 macrophage polarization on cancer progression and prognosis prediction among lung cancer patients with malignant pleural effusions. |
| PubMedID- 25798278 | Response to bevacizumab combination chemotherapy of malignant pleural effusions associated with non-squamous non-small-cell lung cancer. |
| PubMedID- 24887477 | The diagnostic accuracy of il-17 in discriminating between lung cancer with malignant and nonmalignant pleural effusion was compared by constructing receiver operating characteristic (roc) curves. |
| PubMedID- 24720371 | Aim: the aim of this study was to evaluate the diagnostic value of soluble receptor-binding cancer antigen expressed on siso cells (srcas1) and carcinoembryonic antigen (cea) in lung cancer patients with malignant pleural effusion (mpe) and benign pleural effusion (bpe). |
| PubMedID- 23688054 | Prognostic values of vegf and il-8 in malignant pleural effusion in patients with lung cancer. |
| PubMedID- 26301886 | Methods: levels of sb7-h4 and cea in 90 patients with malignant pleural effusion due to lung cancer and 58 patients with benign pleural effusion were measured by elisa. |
| PubMedID- 23178954 | Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion. |
| PubMedID- 25935866 | Material/methods: thirty tpe patients and 20 lung cancer patients with malignant pleural effusion (mpe) were recruited. |
| PubMedID- 24049303 | Our case report illustrates the potential role of curative intent surgery in stage iv lung cancer, with malignant pleural effusion but without distant metastases. |
| PubMedID- 23523589 | The diagnostic value of apolipoprotein e in malignant pleural effusion associated with non-small cell lung cancer. |
| PubMedID- 22744209 | After testing a protocol for ad.cd transfer and lung tumor burden control in a lewis mouse model, we used this technique in the management of lung cancer patients with malignant pleural effusion (mpe): two cases are presented investigating the possible enhancement of anticancer effect in both non-small-cell lung cancer (nsclc) and small-cell lung cancer (sclc) by local activation of the pro-drug 5-fc. |
| PubMedID- 24913066 | It is unknown if pharmacological inhibition of vegf signaling modifies the disease course of non-small-cell lung cancer patients with recurrent malignant pleural effusion. |
| PubMedID- 22363829 | In contrast, the pulmonary edema developed on day 16 in patients 4 who had an underlying lung cancer with malignant pleural effusion obviously resulted from fluid overload. |
| PubMedID- 23925664 | Vascular endothelial growth factor (vegf) is involved in non-small cell lung cancer (nsclc) with malignant pleural effusion (mpe), but little is known regarding the efficacy of bevacizumab (bev) with carboplatin-paclitaxel (cp) for nsclc with mpe. |
| PubMedID- 23656925 | The question addressed was whether surgery could ever be justified in non-small cell lung cancer patients with an unexpected malignant pleural effusion at surgery. |
| PubMedID- 25800577 | It has the characteristics of inhibiting trypsin and high expression in the serum or malignant pleural effusion of patients with lung cancer. |
| PubMedID- 24086497 | lung cancer patients with malignant pleural effusion (mpe) have inferior prognosis, therefore, this group of patients are reclassified as early metastasis (m1a)-stage 4 instead of stage 3b according to the current american joint committee on cancer (ajcc) staging guidelines. |
| PubMedID- 22305792 | Methods: levels of es, vegf and cea in 52 malignant pleural effusion due to lung cancer and 50 patients with non-malignant disease were measured by using sandwich enzyme-linked immunosorbent assay and microparticle enzyme immunoassay. |
Page: 1